Completed PHASE4 INTERVENTIONAL 2-arm
NCT06721442
Effect of Dapagliflozin on Electrocardiographic Parameters in Type 2 Diabetes Patients: DAPA - ECG Study (DAPA-ECG)
Effect of Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, on Ventricular Repolarization Electrocardiographic Parameters in Type 2 Diabetes Patients: DAPA - ECG Study
Sponsor: Beneficência Portuguesa de São Paulo
Conditions
Arrhythmias, Cardiac Diabetes Mellitus
Interventions
Dapagliflozin (DAPA)
Updated 1 time since 2025 Last updated: Dec 5, 2024 Started: Jan 10, 2023 Primary completion: Dec 10, 2023 Completion: Jul 10, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06721442, this PHASE4 trial focuses on Arrhythmias, Cardiac and Diabetes Mellitus and remains completed. Sponsored by Beneficência Portuguesa de São Paulo, it has been updated 1 time since 2023, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
1 version recorded Completed — PHASE4
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Beneficência Portuguesa de São Paulo
- Instituto Dante Pazzanese de Cardiologia
Data source: Beneficência Portuguesa de São Paulo
For direct contact, visit the study record on ClinicalTrials.gov .